Kenvue Shares Rebound Despite Trump’s Tylenol-Autism Claim
Kenvue's stock (KVUE) surged approximately 6% in early trading Tuesday, recovering from a 7% drop the previous day. The rebound occurred despite former President Donald Trump's assertion that acetaminophen—the active ingredient in Kenvue's Tylenol—could be linked to autism in pregnant women.
Trump had characterized Tylenol use during pregnancy as "very dangerous" during a Monday press conference. Kenvue has consistently denied any connection between its flagship product and autism, with interim CEO Kirk Perry recently meeting Health Secretary Robert F. Kennedy Jr. to defend the medication's safety profile.